HBV Citations List: January 2024

Literature Citations

1. CD8 Cis-targeted Il-2 Drives Potent Antiviral Activity against Hepatitis B Virus. Andreata, F., K.D. Moynihan, V. Fumagalli, P. Di Lucia, D.C. Pappas, K. Kawashima, I. Ni, P.H. Bessette, C. Perucchini, E. Bono, L. Giustini, H.C. Nguyen, S.M. Chin, Y.A. Yeung, C.S. Gibbs, I. Djuretic, and M. Iannacone. Science Translational Medicine, 2024. 16(729): eadi1572. PMID[38198572].
[PubMed]. HBV_01_2024.

2. Anti-Hepatitis B Virus Activities of Natural Products and Their Antiviral Mechanisms. Deng, W., F. Chen, Y. Zhao, M. Zhou, and M. Guo. Chinese Journal of Natural Medicines, 2023. 21(11): p. 803-811. PMID[38035936].
[PubMed]. HBV_01_2024.

3. Evaluating the Efficacy of Pegylated IFN-lambda and IFN-alfa Treatments on HBV and HDV Infections in Humanized Mice. Duehren, S., T. Uchida, M. Tsuge, N. Hiraga, A. Abbasi, O. Etzion, J. Glenn, C. Koh, T. Heller, S.J. Cotler, K. Chayama, and H. Dahari. Hepatology, 2023. 78(S1): p. S570-S570. ISI[001094865401199].
[WOS]. HBV_01_2024.

4. Structure-Activity Relationships and Discovery of (S)-6-Isopropyl-2-methoxy-3-(3-methoxypropoxy)-10-oxo-5,10-dihydro-6H-pyrido[1,2-h][1,7]naphthyridine-9-carboxylic acid (Ab-452), a Novel Orally Available HBV RNA Destabilizer. Gotchev, D., B.D. Dorsey, D. Nguyen, R. Kakarla, B. Dugan, S. Chen, M. Gao, L. Bailey, F. Liu, T. Harasym, T. Chiu, S. Tang, A.C. Lee, A.G. Cole, and M.J. Sofia. Journal of Medicinal Chemistry, 2024. 67(2): p. 1421-1446. PMID[38190324].
[PubMed]. HBV_01_2024.

5. Two New Terpenoid Glycosides from Isodon Macrocalyx. Liang, X., Y. Chang, X. Guan, Y. Huang, L. Pan, J. Li, and J. Li. Natural Product Research, 2024. 38(2): p. 220-226. PMID[35983850].
[PubMed]. HBV_01_2024.

6. Screening of Low Molecular Compounds That Inhibit Binding of Envelope and Capsid of Hepatitis B Virus. Sato, K., J. Inoue, M. Ninomiya, A. Sano, M. Tsuruoka, S. Sawahashi, and A. Masamune. Hepatology, 2023. 78(S1): p. S589-S589. ISI[001094865401218].
[WOS]. HBV_01_2024.

7. Development of Tenofovir monobenzyl ester phosphonoamidate Prodrugs with Improved anti-Hepatitis B Virus Activity and Intrahepatic Tenofovir Enrichment. Sun, X., L. Song, L. Lin, A. Ding, C. Wang, X. Ma, S. Zhou, J. Cai, and H. Tang. Bioorganic & Medicinal Chemistry, 2024. 99: 117607. PMID[38246114].
[PubMed]. HBV_01_2024.

8. In Vitro and in Vivo Profiling of an Orally Bioavailable Small Molecule Inhibiting Hepatitis B Virus by Mimicking Interferon Alpha. Tang, A., L.D. Guo, L. Li, F. Tramontini, C. Li, N. Unchwaniwala, M. Shen, J.X. Yu, H. Pajouhesh, M.P. Windisch, M. Perron, M.A. Walker, W. Delaney, M. Zhong, and K. Zhang. Hepatology, 2023. 78(S1): p. S574-S575. ISI[001094865401204].
[WOS]. HBV_01_2024.

9. Gambogic acid Inhibits HBX-mediated Hepatitis B Virus Replication by Targeting the DTX1-Notch Signaling Pathway. Wen, X., D. Li, P. Chen, M. Tan, H. Zhang, Y. Liu, J. Ren, and S. Cheng. Virus Research, 2024. 339: 199273. PMID[38029800]. PMCID[PMC10714370].
[PubMed]. HBV_01_2024.

Patent Citations

This month, no relevant HBV patents were identified.